In a multicenter retrospective analysis, when 56 NSCLC patients with an AID received a PD-L1 inhibitor, 23% of them had an exacerbation of AID, and 38% of patients developed irAE [42]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.